Pfizer, Geron Downsize to Streamline Costs

Pfizer is cutting more than 200 jobs in Switzerland, shrinking its Swiss headcount from about 300 to around 70 employees as part of an ongoing global cost‑cutting and restructuring drive.1 5

The Swiss workforce reduction is expected to be completed by year‑end, with Pfizer describing the move as an effort to “streamline and realign” resources and reduce operational complexity.1 5

These cuts are part of a multi‑year cost realignment program launched in October 2023, through which Pfizer has already eliminated roughly 2,000 positions globally, including about 850 roles in 2023, 700 in 2024, and around 150 so far in 2025, excluding the new Swiss reductions.1

Pfizer has publicly targeted $4.5 billion in net cost savings by the end of 2025, and the Swiss layoffs contribute to this broader savings goal.5

Geron Corporation has announced a strategic restructuring plan that will cut approximately one‑third of its current workforce of about 260 employees, affecting roughly 87 staff.1 2 3

Geron’s layoffs are aimed at reducing operating expenses and reinvigorating sales of its myelodysplastic syndromes cancer therapy Rytelo, with savings to be redeployed to strengthen the drug’s commercial strategy and execution.1 3 4

The restructuring is expected to be substantially complete in the first quarter of 2026, with Geron projecting that full‑year 2026 operating expenses will be lower than 2025 levels, and that savings will begin to be realized in the first quarter of 2026.1 3

Geron has framed the move as a long‑term value creation initiative, indicating it will incur some restructuring costs but expects a meaningful impact on 2026 operating expenses and an improved ability to meet patient needs.3

Industry trackers note that both Pfizer’s Swiss cuts and Geron’s one‑third workforce reduction are part of a broader 2025 biopharma layoff trend focused on extending cash runways, cutting operating costs, and refocusing pipelines and commercial priorities.1 2